The Vaccine Group Welcomes Two New Directors to its Board
The Vaccine Group (TVG) is pleased to announce the appointment of Neil Crabb and Professor Laura Bowater, MBE, to its Board of Directors. Neil Crabb
22 June 2026
Designed for a lifetime of active immunity – even in the presence of maternal antibodies
Providing expertise in veterinary medicine and market impact analysis
Microbiology and bioinformatics expertise with a focus on genomic characterisation
CRO with expertise in animal studies and challenge model development
Council of UK research and innovation supporting the most promising UK deep tech businesses.
Designed to overcome maternal-antibody interference enabling vaccination during the critical early-life window
Rapid, modular ‘plug and play’ Bacterial Artificial Chromosome (BAC)-based synthetic biology
Robust vector designed for sustained immune responses and long lasting protection
Ability to differentiate infected from vaccinated animals (DIVA), supporting surveillance programmes and regulatory acceptance
Targeting high-impact viral and bacterial diseases in livestock, with expansion into selected companion animal diseases.
Early-life respiratory protection in calves, including in the presence of maternally-derived antibodies (MDA).
Indicative at risk calf populations:
Market Opportunity:
BRSV sits within a significant cattle-health opportunity shaped by two major windows of vulnerability: early life, when maternally-derived antibodies can limit vaccine effectiveness, and post-weaning, when stress and commingling increase disease risk.
TVG’s lead programme is designed to address the early-life protection gap, with clear relevance in major cattle markets such as the UK and USA and broader significance across global livestock systems.
Stage:
Key Differentiators:
To find out more about our candidate vaccine pipeline, click below:
Cross-serotype bacterial protection in piglets, advancing vaccine solutions to antimicrobial resistance (AMR) and herd health.
Lumpy Skin Disease (LSD)
Bovine tuberculosis (bTB)
Bovine mastitis
African swine fever (ASF)
Porcine reproductive and respiratory syndrome (PRRS)
Porcine circovirus-2 (PCV2)
Porcine cysticercosis
Canine leishmaniasis
Feline immunodeficiency virus (FIV)
Equine influenza virus (EIV)
Canine oncology
Canine leishmaniasis
Feline immunodeficiency virus (FIV)
Equine influenza virus (EIV)
Canine oncology
Latest News
The Vaccine Group (TVG) is pleased to announce the appointment of Neil Crabb and Professor Laura Bowater, MBE, to its Board of Directors. Neil Crabb
The Vaccine Group was pleased to see TVG CEO Dr Jeremy Salt contribute expertise to the recent STAR IDAZ International Research Consortium meetings in Ottawa,
The Vaccine Group’s bovine respiratory syncytial virus (BRSV) vaccine programme has been recognised in the 2025 Animal Research Breakthroughs Review published by Understanding Animal Research, highlighting the
TVG is delighted to announce that a vaccine candidate to tackle Streptococcus suis (“S.suis”) in pigs developed with University of Plymouth using grant funding from
The Vaccine Group (TVG) has demonstrated outstanding results in a cattle challenge trial conducted by the UK government’s Animal and Plant Health Agency using a
